INTRODUCTION

Cervical cancer is the second leading cause of cancer mortality among women worldwide (Łuczak and Jagodzinski, 2008; Chang et al., 2010; Rho et al., 2022). Over the past two decades, numerous studies have suggested that high-risk HPV plays an important role in the development and pathogenesis of cervical cancer (Guo et al., 2011; Arbyn et al., 2021). Currently, more than 100 HPV genotypes exist, and ~40 of them infect the genital mucosa. These HPVs are classified into low-risk or high-risk types based on their malignant lesion level in the cervix. The high-risk type is associated with more than 90% of cervical cancers (Dell and Gaston, 2001; Gyöngyösi et al., 2012; Davies-Oliveira et al., 2021).

High-risk HPV encodes two transforming genes, E6 and E7, both of which play important roles in malignant transformation (Zhou et al., 2012; Malla and Kamal, 2021). HPV E6 binding to p53 is mediated by the E6-associated protein ligase (E6-AP), which targets p53 for ubiquitination and subsequent proteasomal degradation (Nuber et al., 1998; Zhang et al., 2022).

E7 is a major transforming protein of HPV and its transforming activity is due to its interaction with retinoblastoma tumor suppressor (Rb) (Thierry, 2009; Moody and Laimins, 2010; Xiong et al., 2022). The conserved LXCXE motif of the E7 protein is crucial for E7/Rb binding, and it accelerates the proteasomal degradation of Rb (Putta et al., 2022). Additionally, the NH2-terminal segment of the E7 protein is required for Rb degradation, but it is not required for Rb binding (Patrick et al., 1994; Gonzalez et al., 2001; Fiedler et al., 2004; Sima et al., 2008; Zhou et al., 2022) and the carboxyl terminus of the E7 can bind to many cellular proteins and can be an additional determinant for cellular transformation (Wu et al., 1993a; Vats et al., 2022).

Abstract

The human papillomavirus (HPV)-18 E7 (E7) oncoprotein is a major transforming protein that is thought to be involved in the development of cervical cancer. It is well-known that E7 stimulates tumour development by inactivating pRb. However, this alone cannot explain the various characteristics acquired by HPV infection. Therefore, we examined other molecules that could help explain the acquired cancer properties during E7-induced cancer development. Using the yeast two-hybrid (Y2H) method, we found that the Elk-1 factor, which is crucial for cell proliferation, invasion, cell survival, anti-apoptotic activity, and cancer development, binds to the E7. By determining which part of E7 binds to which domain of Elk-1 using the Y2H method, it was found that CR2 and CR3 of the E7 and parts 1–206, including the ETS-DNA domain of Elk-1, interact with each other. As a result of their interaction, the transcriptional activity of Elk-1 was increased, thereby increasing the expression of target genes EGR-1, c-fos, and E2F. Additionally, the colony forming assay revealed that overexpression of Elk-1 and E7 promotes C33A cell proliferation. We expect that the discovery of a novel E7 function as an Elk-1 activator could help explain whether the E7 has novel oncogenic activities in addition to p53 inactivation. We also expect that it will offer new methods for developing improved strategies for cervical cancer treatment.

Key Words: HPV-18 E7, Elk-1, Cervical cancer, Yeast two-hybrid, Protein-protein interaction, Transcriptional activity

Original Article

Biomol Ther 30(6), 593-602 (2022)

Corresponding Authors

E-mail: uatheone@dongguk.edu (Lee CH), shlee@yongin.ac.kr (Lee SH)
Tel: +82-31-961-5213 (Lee CH), +82-31-8020-2780 (Lee SH)
Fax: +82-31-961-5206 (Lee CH), +82-31-8020-2886 (Lee SH)

The first two authors contributed equally to this work.
High-risk HPV E7 protein binds to pRb with a higher affinity when compared to low-risk HPV. High-risk HPV E7 binding to pRb results in hyperphosphorylation of pRb and release of the E2F transcription factor, which activates cell proliferation genes and reverses G1-S arrest (Hwang et al., 2002; Minoni et al., 2020). Furthermore, E7 modulates cell cycle regulation through the inhibition of cyclin-dependent kinase inhibitors (p21 and p27), stimulation of cyclins, and direct activation of cyclin-dependent kinases (CDKs) (Narisawa-Saito and Kiyo-no, 2007; Ci et al., 2020). Recent findings suggest that E7, which is independent of pRb, may contribute to the transformation of target cells (Balsitis et al., 2005; Hatterschide et al., 2022; Wendel et al., 2022).

In this study, the Elk-1 transcription factor was identified as an interaction partner for the E7 oncoprotein. We demonstrated in vitro and in vivo interactions between Elk-1 and the E7 protein using glutathione S-transferase (GST) pull-down assays, co-immunoprecipitations, Western blot analyses, and Y2H assays. We also investigated the specific binding sites between these two proteins and the physiological consequence of their interaction. We discovered that E7 enhanced the transcriptional activity of Elk-1 and induced the expression of the target gene products.

We suggest that Elk-1 transcriptional activity should be increased for the formation of a novel oncogenic action of E7 in cervical cancer through its interaction with E7. Our findings may provide a new logic for inhibiting E7-induced carcinogenesis.

**MATERIALS AND METHODS**

**Plasmid construction**

The pCMV-GAL4/Elk-1 plasmid was constructed by cloning EcoRI fragments from pCDNA3.1/Elk-1 into same site as pCMV-GAL4 (Stratagene, La Jolla, CA, USA). To construct Histagged E7, EcoRI/XhoI polymerase chain reaction (PCR) fragments were cloned into the same sites as pCDNA4-His (Invitrogen, Waltham, MA, USA). The following plasmids were constructed for use in the GST pull-down assays: GST-E7 was constructed by cloning EcoRI/XhoI fragments from pCDNA4-His/E7 into same sites as pGEX-4T-1. For the E7 deletion mutants, GST-E7 (1-20), GST-E7 (21-40), and GST-E7 (41-106) were constructed by cloning EcoRI/XhoI PCR fragments into same sites as pGEX-4T-1. Various deletion mutant fragments were cloned by PCR using the appropriate sets of primers (Table 1). GST-E7 (∆25-29) and GST-E7 (L25A) mutants within the pRb-binding domain of E7 were constructed using the Quick-Change™ Site-Directed Mutagenesis Kit (Stratagene).}

**Table 1. List of primer sequences used for the deletion mutants or site-directed mutagenesis**

| Gene Primer sequences | Primer sequences |
|-----------------------|------------------|
| E7 (1~20)             | Forward: 5'-GATCGAATTACATGCATGGACCTAAGGCA-3' |
|                       | Reverse: 5'-GATCCTCGAGTTCATTCTTCTA-3' |
| E7 (21~40)            | Forward: 5'-GATCGAATTACATGATTCCGGTTGA-CCTTCTA-3' |
|                       | Reverse: 5'-GATCCTCGAGTTCATTCTTCTA-3' |
| E7 (41~106)           | Forward: 5'-GATCGAATTACATGATTCCGGTTGA-CCTTCTA-3' |
|                       | Reverse: 5'-GATCCTCGAGTTCATTCTTCTA-3' |
| Elk-1 (1~117)         | Forward : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
|                       | Reverse : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
| Elk-1 (118~199)       | Forward : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
|                       | Reverse : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
| Elk-1 (200~286)       | Forward : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
|                       | Reverse : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
| Elk-1 (287~339)       | Forward : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
|                       | Reverse : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
| Elk-1 (340~428)       | Forward : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
|                       | Reverse : 5'-ATGCCGATCCGATGCCGCGGGTTGTTATG-3' |
| E7 (∆25~29)           | Forward: 5'-GATCGAATTACATGCATGGACCTAAGGCA-3' |
|                       | Reverse: 5'-GATCGAATTACATGCATGGACCTAAGGCA-3' |
| E7 (L25A)             | Forward: 5'-GATCGAATTACATGCATGGACCTAAGGCA-3' |
|                       | Reverse: 5'-GATCGAATTACATGCATGGACCTAAGGCA-3' |

**Cell culture and transfection**

Human cervical cancer cell lines were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in recommended medium supplemented with 10% fetal bovine serum (JBI, Seoul, Korea) and 1% penicillin/streptomycin at 37°C. Transfections were performed using FuGENE6 (Promega, Madison, WI, USA) with indicated amounts of expression plasmids.

**Yeast two-hybrid screening and β-galactosidase assay**

Yeast two-hybrid screening was performed using the Matchmaker LexA two-hybrid system (Clontech, Mountain View, CA, USA) according to the manufacturer’s instructions (Rho et al., 2021b). Briefly, E7 cDNA was cloned into the pGilda bait vector as described above and human ovary cDNA library used as prey vector. Bait and prey vectors were co-transformed in the EGY48 yeast strain using the lithium acetate method, and positive clones were selected on synthetic dropout medium lacking leucine, tryptophan, histidine, and uracil. To construct His-tagged E7, EcoRI/XhoI polymerase chain reaction (PCR) fragments were cloned into the same sites as pCDNA4-His (Invitrogen, Waltham, MA, USA). The following plasmids were constructed for use in the GST pull-down assays: GST-E7 was constructed by cloning EcoRI/XhoI fragments from pCDNA4-His/E7 into same sites as pGEX-4T-1. For the E7 deletion mutants, GST-E7 (1-20), GST-E7 (21-40), and GST-E7 (41-106) were constructed by cloning EcoRI/XhoI PCR fragments into same sites as pGEX-4T-1. Various deletion mutant fragments were cloned by PCR using the appropriate sets of primers (Table 1). GST-E7 (∆25~29) and GST-E7 (L25A) mutants within the pRb-binding domain of E7 were constructed using the Quick-Change™ Site-Directed Mutagenesis Kit (Stratagene).
tive clones were further confirmed using the β-galactosidase assay with 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal).

**GST pull-down assay**

Equal amounts of GST and GST fusion proteins bound to glutathione-linked agarose beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK) were incubated in vitro with translated radiolabeled proteins for 1 h at room temperature in a binding buffer containing 50 mM Tris–HCl (pH 8.0), 1% NP-40, and 2 mM EDTA. The [35S]-Met labeled proteins were produced using the TNT® Quick Coupled Transcription/Translation System (Promega) according to the manufacturer’s instructions. Bound proteins were washed three times in buffer (binding buffer plus 10% glycerol and 150 mM NaCl). SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and autoradiography were used to analyze the patterns of bound proteins.

**Luciferase assay**

The luciferase assays were performed using the Dual-Luciferase® Reporter Assay System (Promega) (Rho et al., 2021a). Twenty-four hours after transfection, the cells were cultured in 35-mm plates and lysed in 100 μL of passive lysis buffer; 20 μL of the cell lysate was mixed with 100 μL of luciferase assay reagent II (LAR II) in a 96-well white plate. Then, 100 μL of Dual-Glo® Stop & Glo® Reagent (Promega) was added to each sample being assayed at 405 nm in a luminometer (PerkinElmer Inc., Waltham, MA, USA) for 15 min and washed with distilled water before quantitation.

**Co-immunoprecipitation**

At 48 h post-transfection, cells were harvested and lysed on ice in RIPA buffer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% Na-deoxycholate] (Rho et al., 2022). After centrifugation at 13,000 rpm, the supernatant was incubated with the appropriate antibodies [anti-His (H-3) and anti-E7 (N-19); Santa Cruz Biotechnology, Dallas, TX, USA] overnight at 4°C and then with protein A/G beads (Upstate Biotechnology, Lake Placid, NY, USA) for 3 h. The beads were washed three times with buffer containing 50 mM Tris–HCl (pH 8.0), 1% NP-40, and 2 mM EDTA. Immunoprecipitates were suspended in Laemmli sample buffer and boiled for 5 min. For the immunoprecipitation of endogenous proteins, cells were treated with 5 mM DTBP (dimethyl 3,3′-dithiobispropionimidate-2HCl); Pierce Biotechnology, Waltham, MA, USA) at 4°C for 30 min before harvesting. The cross-linking reaction was stopped by the addition of a wash buffer containing 150 mM NaCl and 100 mM Tris-HCl (pH 8.0). Subsequent procedures were the same as those described above.

**Western blotting**

Cells were lysed and equal amounts of cell extracts (20-40 μg) or the samples from the co-immunoprecipitations were electrophoresed on 10% SDS polyacrylamide gel, electro transferred onto a nitrocellulose membrane (Yoon et al., 2020). The membrane was incubated with the appropriate primary antibody and horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized by enhanced chemiluminescence (ECL Western blotting detection; Bio-Rad, Hercules, CA, USA).

**Colony formation assay**

For the colony formation assay, 1,000 cells transfected with E7-, Elk-1-, and En-expressing vectors and a control vector plasmid were seeded on 100-mm plates and allowed to grow for 14 days in culture medium (Choi et al., 2020). The cell colonies were stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) for 15 min and washed with distilled water before quantitation.

**Data analysis and statistics**

Values are presented as the mean ± SD or ± SE. Statistical comparisons between groups were performed using the Student’s t-test. p<0.05 was considered statistically significant.

**RESULTS**

**E7 interaction with Elk-1**

E7-binding proteins were screened using the Y2H system to identify novel interaction proteins of the E7. The pGilda-E7 was used as bait to screen a human cDNA library. Based on the results, Elk-1 was identified as an interacting partner. Growth and β-galactosidase assays were conducted to verify the result of the Y2H screening (Fig. 1).

Strains transformed with pGilda/Elk-1 and pB42AD/E7 were further confirmed using the β-galactosidase assay with 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal).

**GST pull-down assay**

Equal amounts of GST and GST fusion proteins bound to glutathione-linked agarose beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK) were incubated in vitro with translated radiolabeled proteins for 1 h at room temperature in a binding buffer containing 50 mM Tris–HCl (pH 8.0), 1% NP-40, and 2 mM EDTA. The [35S]-Met labeled proteins were produced using the TNT® Quick Coupled Transcription/Translation System (Promega) according to the manufacturer’s instructions. Bound proteins were washed three times in buffer (binding buffer plus 10% glycerol and 150 mM NaCl). SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and autoradiography were used to analyze the patterns of bound proteins.

**Luciferase assay**

The luciferase assays were performed using the Dual-Luciferase® Reporter Assay System (Promega) (Rho et al., 2021a). Twenty-four hours after transfection, the cells were cultured in 35-mm plates and lysed in 100 μL of passive lysis buffer; 20 μL of the cell lysate was mixed with 100 μL of luciferase assay reagent II (LAR II) in a 96-well white plate. Then, 100 μL of Dual-Glo® Stop & Glo® Reagent (Promega) was added to each sample being assayed at 405 nm in a luminometer (PerkinElmer Inc., Waltham, MA, USA) for 15 min and washed with distilled water before quantitation.

**Co-immunoprecipitation**

At 48 h post-transfection, cells were harvested and lysed on ice in RIPA buffer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% Na-deoxycholate] (Rho et al., 2022). After centrifugation at 13,000 rpm, the supernatant was incubated with the appropriate antibodies [anti-His (H-3) and anti-E7 (N-19); Santa Cruz Biotechnology, Dallas, TX, USA] overnight at 4°C and then with protein A/G beads (Upstate Biotechnology, Lake Placid, NY, USA) for 3 h. The beads were washed three times with buffer containing 50 mM Tris–HCl (pH 8.0), 1% NP-40, and 2 mM EDTA. Immunoprecipitates were suspended in Laemmli sample buffer and boiled for 5 min. For the immunoprecipitation of endogenous proteins, cells were treated with 5 mM DTBP (dimethyl 3,3′-dithiobispropionimidate-2HCl); Pierce Biotechnology, Waltham, MA, USA) at 4°C for 30 min before harvesting. The cross-linking reaction was stopped by the addition of a wash buffer containing 150 mM NaCl and 100 mM Tris-HCl (pH 8.0). Subsequent procedures were the same as those described above.

**Western blotting**

Cells were lysed and equal amounts of cell extracts (20-40 μg) or the samples from the co-immunoprecipitations were electrophoresed on 10% SDS polyacrylamide gel, electro transferred onto a nitrocellulose membrane (Yoon et al., 2020). The membrane was incubated with the appropriate primary antibody and horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized by enhanced chemiluminescence (ECL Western blotting detection; Bio-Rad, Hercules, CA, USA).

**Colony formation assay**

For the colony formation assay, 1,000 cells transfected with E7-, Elk-1-, and En-expressing vectors and a control vector plasmid were seeded on 100-mm plates and allowed to grow for 14 days in culture medium (Choi et al., 2020). The cell colonies were stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) for 15 min and washed with distilled water before quantitation.

**Data analysis and statistics**

Values are presented as the mean ± SD or ± SE. Statistical comparisons between groups were performed using the Student’s t-test. p<0.05 was considered statistically significant.

**RESULTS**

**E7 interaction with Elk-1**

E7-binding proteins were screened using the Y2H system to identify novel interaction proteins of the E7. The pGilda-E7 was used as bait to screen a human cDNA library. Based on the results, Elk-1 was identified as an interacting partner. Growth and β-galactosidase assays were conducted to verify the result of the Y2H screening (Fig. 1).

Strains transformed with pGilda/Elk-1 and pB42AD/E7
transfected with 10 µg of pCDNA4-His/E7 (lanes 1, 3 and 4) in the absence or presence of RasV12 (lanes 4). Cells were harvested from 48 h post-transfection and whole-cell lysates were immunoprecipitated with an anti-His antibody (Santa Cruz Biotechnology). Immunoprecipitations were separated on 10% SDS-PAGE gels and blotted with an anti-Elk-1 antibody (Santa Cruz Biotechnology). (B) HeLa cells were transiently transfected with pCDNA3.1/Elk-1 and pEGFP-C1/E7. Cells were fixed and subjected to indirect immunofluorescence using an anti-Elk-1 antibody (Santa Cruz Biotechnology) from HeLa cells. Immunoprecipitations were separated on 10% SDS-PAGE gels and blotted with an anti-Elk-1 antibody (Santa Cruz Biotechnology). (C) HEK293a cells were transiently transfected with pCDNA3.1/Elk-1 and pEGFP-C1/E7. Cells were fixed and subjected to indirect immunofluorescence using an anti-Elk-1 antibody (a, Santa Cruz Biotechnology) followed by DAPI (d) and GFP antibody (b) counterstaining. A merged image of Elk-1 and GFP-E7 immunostaining is shown in (c). Images were representative of three independent experiments.

were unable to grow in normal culture media, but those grown in a Leu-deficient culture medium were able to grow (Fig. 1A). The culture medium containing X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) turned blue after X-Gal had been decomposed by β-galactosidase (Fig. 1B), demonstrating a strong interaction between the E7 and Elk-1.

To further investigate this interaction, an in vitro GST pull-down assay was performed. Bacterially expressed GST and GST-E7 fusion proteins were immobilised on glutathione-linked agarose beads, and a radioactively labelled Elk-1 protein was prepared by in vitro transcription after translation using 35S-methionine (Fig. 1C). The GST-E7 fusion protein was incubated with the radiolabelled Elk-1 protein. The complexes were washed, separated on SDS-PAGE gels, and analysed by autoradiography, and the GST fusion proteins were separated on gels for quantitation. As seen in Fig. 1D, the GST-E7 fusion proteins successfully pulled down 35S-Elk-1 in the assay, whereas GST alone failed to interact with 35S-Elk-1. These results showed that Elk-1 interacted directly with the E7 oncoprotein in vitro.

**Elk-1 interaction and co-localisation with E7 in cells**

To determine the feasibility of Elk-1 and E7 association in mammalian cells, Elk-1 and His-E7 were transiently co-transfected into human HEK293a cells for immunoprecipitation analysis.

After 48 h of transfection, cell lysates were prepared and co-immunoprecipitation assays were performed using an anti-His (His-E7) antibody. As shown in Fig. 2, Elk-1 co-precipitated with the His-E7 antibody. However, Ras overexpression slightly increased the interaction between Elk-1 and E7 in the HEK293a cells (Fig. 2A, lane 4).

The co-immunoprecipitation assays were repeated in HeLa cells to express the endogenous E7 protein. The HeLa cells were transfected with Elk-1 and treated with 5 mM DTBP before cell lysis to preserve the intracellular protein complexes in the lysates. Cell lysates from the HeLa cells underwent co-immunoprecipitation with the E7 antibody, and the immune complexes were subsequently analysed by Western blotting using the Elk-1 antibody. As shown in Fig. 2B, Elk-1 co-precipitated with the E7 antibody, but not with a control IgG antibody (Fig. 2B, lane 1).

To further confirm the interaction between Elk-1 and E7 in vivo, we investigated Elk-1 and E7 localisation within the same cellular compartments. To this end, HEK293a cells were co-transfected with Elk-1 and GFP-E7 (green fluorescent E7 protein). The anti-Elk-1 antibody identified Elk-1 in a widespread pattern of expression throughout the cytoplasm and nucleus (Fig. 2C-a). A similar localisation pattern was also observed for the GFP-E7 (Fig. 2C-b). Combined images showed the pattern of Elk-1 and GFP-E7 co-localisation, which was more evident in the endoplasmic reticulum connected to a nuclear membrane where both proteins were overexpressed (Fig. 2C-c). The location of the nucleus was determined by DAPI staining, as shown in Fig. 2C-d.

These results revealed the in vivo interaction between Elk-1 and E7 in mammalian cells, and Elk-1 and E7 co-localised in the same cellular compartments, further confirming the intercellular interactions.

**Identification of the Elk-1-binding domain from E7**

To investigate the specific Elk-1 binding domain of E7, three E7 truncation fragments were designed, as shown in Fig. 3A. In the Y2H system, full-length human Elk-1 cDNA and a plasmid containing either the full-length E7 cDNA (1–106) or three deletion fragments (CR1 (1–20), CR2 (21–40), or CR3
Identification of the E7-binding domain in Elk-1

The E7 domains that interacted with Elk-1 were identified, but the potential Elk-1 motifs involved in E7 interaction were yet to be identified. To this end, a series of GST-Elk-1 derivative proteins were constructed (Fig. 4A). First, to confirm that full-length Elk-1 interacted with E7, (His6)-Elk-1 (immobilised on Ni2+-NTA agarose beads) was used in the pull-down assays. The bound E7 was examined by autoradiography (Fig. 4B).

GST pull-down assays were then performed using GST-Elk-1 deletion proteins and in vitro translated E7. As shown in Fig. 4C, E7 had a higher affinity for binding GST-Elk-1 (1–206) than GST-Elk-1 (1–89) (Fig. 4C top, lanes 3 and 4). Additionally, GST-Elk-1 (148–260) showed weak binding to E7 (Fig. 4C top, lane 5), while no significant binding was observed for Elk-1 spanning residue fragments 230–260 and 307–428 (Fig. 4C top, lanes 6 and 7). The interaction sites between E7 and Elk-1 in vivo were also analysed, and the results of the growth and β-galactosidase assays with the yeast system were consistent with the GST pull-down assay result (Fig. 4D).

Together, these results suggest that the N-terminal domain of Elk-1 including the ETS DNA-binding domain and serum response factor (SRF) binding domain was required for E7 association.

Enhancement of Elk-1 transcriptional activity by E7 for the elevation of Egr-1 and c-fos protein expression

To clarify the functional consequences of the interaction between E7 and Elk-1, the role of E7 in controlling the transcription capacity of Elk-1 was investigated. First, the promoter activity of the Elk-1 target genes, egr-1 and c-fos, were evaluated. The egr-1 or c-fos promoter-reporter gene construct was co-transfected into cells together with plasmid vectors that expressed E7, Elk-1, and Elk-En (a dominant-negative form of Elk-1) (Fig. 5).

In HeLa cells, transient transfection of Elk-1 stimulated the promoter activity of both egr-1 and c-fos, as expected (Fig. 5A, 5B). However, E7 also stimulated the promoter activity of the two Elk-1 target genes. The intensity of activation of the egr-1 promoter by Elk-1 and/or E7 was much stronger than that of the c-fos promoter (Fig. 5A, 5B). Moreover, when E7 and Elk-1...
were co-transfected, a synergistic effect was observed on the activation of the Elk-1 target gene promoter. Egr-1 promoter activity was increased by ~35-fold, and c-fos promoter activity was increased by ~4-fold. These results suggested that E7 enhanced Elk-1 transactivation activity. To confirm that E7 binding to Elk-1 enhanced transactivation, Elk-En was transiently transfected with E7. The results showed that upregulation of Egr-1 and c-fos promoter activity by E7 was significantly downregulated by Elk-En, suggesting that E7 interacted with Elk-1 to enhance transcriptional activity. In contrast, the expression of the E2F transcription factor activated by E7 (not the target gene of Elk1) was not increased by co-transfection with Elk-1 and E7 or decreased by co-transfection with Elk1-EN and E7 (Fig. 5C).

After transiently transflecting E7, the expression of the egr-1 and c-fos proteins was investigated since E7 increased the transcriptional activity of Elk-1. Cells were co-transfected with $2 \mu g$ of the E7-expressing vector and various amounts of the E7-expressing vector ($0, 2, 5, \text{and } 8 \mu g$), and the protein expression levels of egr-1 and c-fos were examined using a Western hybridisation assay. In both HeLa (HPV positive) and C33A (HPV negative) cell lines, cells transiently transfected with E7 exhibited increased protein expression levels of egr-1 and c-fos in a dose-dependent manner (Fig. 5D, 5E). These results suggest that E7 upregulated the expression of target gene products egr-1 and c-fos while activating the transcriptional activity of Elk-1.

Effects of the co-transfection of E7 and Elk-1 on cancer cell proliferation

To determine the synergistic effects of the E7 and Elk-1 on cervical cancer cell proliferation, a colony formation assay was performed in the C33A cells. Transfection of E7 or Elk-1 induced colony formation of C33A cells. More importantly, the co-transfection of E7 and Elk-1 resulted in increased colony formation (Fig. 6A, 6B). However, compared to the untreated control and E7-treated cells, Elk-En significantly reduced colony formation in C33A cells. These results suggest that E7 significantly increased cell proliferation.

DISCUSSION

High-risk HPV encodes oncogenes E6 and E7, which have transforming properties. According to several studies, E6 and E7 are potent oncogenes that promote cervical cancer devel-
Fig. 5. E7 enhances the transcriptional activity of Elk-1. Luciferase reporter assays for the activity of egr-1 (A), c-fos (B), and the E2F (C) promoter were performed with the expression vectors encoding Elk-1, Elk-En, and E7, as indicated. At 48 h post-transfection, the cells were harvested. Luciferase activity was normalized with respect to the Renilla luciferase activity. Values are expressed as the means ± SD from three experiments. (D, E) Effects of E7 on the expression levels of egr-1 and c-fos in HeLa and C33A cell lines. HeLa (D) and C33A (E) cells were transiently transfected with pCDNA3.1/Elk-1 and pCDNA4-His/E7. Whole-cell extracts were collected at 48 h after transfection. Egr-1 and c-fos were detected by Western hybridization analysis.

Fig. 6. Effects of E7, Elk-1, and Elk-En on cell proliferation. (A) Colony formation in C33A cells treated with Elk-1, E7, and Elk-En in modified Eagle’s medium (MEM) containing 10% fetal bovine serum (FBS). Cell numbers were determined after incubation for 10 days. (B) Values are expressed as the means ± SD from two experiments.
opment (Yim and Park, 2005; Pal and Kundu, 2020).

As previously stated, one of the major oncogenic functions of E7 is the inactivation of pRb through proteasome degradation induction. However, some mutants with changes to the CK2 site or C-terminal zinc finger domain inhibit the transforming activity of E7 while maintaining their ability to bind to pRb (McIntyre et al., 1993). Additionally, many researchers have reported that pRb inactivation was necessary, but not sufficient for the transformation by E7 and suggested that another cellular target was needed for full E7-induced transformation (Prathapam et al., 2001; Taghizadeh et al., 2019; Wang et al., 2021). Research into E7-related host proteins is necessary for establishing potential future therapeutic strategies in the management of cervical cancer.

In this case, a Y2H method was used to examine a partner molecule that binds to E7 to discover a new E7 mechanism in the carcinogenesis of human cervical cancer. Elk-1 was identified as a binding partner capable of interacting with E7. Elk-1, a transcriptional activator of a proto-oncogene from the ETS family of transcription factors, binds to the serum response element (SRE) in the promoter region and mediates transcriptional activity in response to growth factors. Elk-1 has a significant role in regulating ras-induced tumorigenesis in lung cancer cells (De Luca et al., 2012; Yang et al., 2012; Inoue et al., 2018). In prostate cancer cells, Elk-1 was identified as a transcription factor that regulates the transcriptional activation of EGR1 by an epidermal growth factor (EGF). In particular, the Elk-1 bond at the SRE site of the EGR1 promoter was sufficient for EGF-mediated EGR1 expression (Gregg and Fraizer, 2011; Yang et al., 2020). In breast cancer cells, EGF-induced activation of Elk-1 contributed to cell survival through Mcl-1 regulation (Booy et al., 2011; Winder and Campbell, 2022).

Elk-1 functions as a cofactor to enable the activation of the c-myc promoter by the nuclear factor of the activated T cells (NFAT) and pancreatic cancer growth in vitro and in vivo (Wang et al., 2018; Aia, 2022). Androgen receptor activation in bladder cancer cells increased c-fos expression after Elk-1 expression, resulting in cell proliferation, migration, and invasion (Kawahara et al., 2015). Despite these extensive studies, the function of Elk-1 in cervical cancer is poorly understood.

We demonstrated the direct binding of E7 to Elk-1 (Fig. 1, 2). Deletion constructs were used to locate the Elk-1-interacting region of E7. The E7 protein is divided into three domains [conserved regions (CR) 1–3]. CR1 at the N-terminus was required for the cellular transformation and pRb degradation but did not directly bind to pRb; CR2, which contained an LXCXE motif sufficient for binding to pRb, blocked the association of E2F and pRb; and CR3, which contained two Cys-X-X-Cys motifs that bind directly to a C-terminal region of pRb, was also required to inhibit the binding of E2F to pRb. The CR3 region of E7 includes a nuclear export signal (NES) and type 1 PDZ binding motifs (Chenes et al., 2012).

All E7 deletion constructs (CR1, CR2, and the CR3 domain) bonded to Elk-1, but Elk-1 interacted more strongly with the CR2 and CR3 domains than with the CR1 domain (Fig. 3, 4). Additionally, the LXCXE pRb-binding motif of the E7 mutants (deletion or deficient in the pRb-binding motif) did not bind to Elk-1, suggesting that the LXCXE motif was required for binding Elk-1 to E7 (McIntyre et al., 1993). Our results suggest that the pRb-binding motif in E7 was crucial for Elk-1 interaction and that Elk-1 may contribute to E7/pRb binding in E7 biological activity (Edmonds and Vousden, 1989; Jones and Münger, 1997; Jones et al., 1997; Aarthy et al., 2018).

Next, the E7-interacting region in Elk-1 was identified. E7 binds to the ETS DNA-binding and SRF-binding domains of Elk-1. Elk-1 was recruited to the SRE via protein–DNA (via ETS DNA binding) and protein–protein (via the SRF-binding domain) interactions. The ETS DNA-binding domain, which is located in the N-terminal region, was required for DNA binding and ternary complex formation with SRF. The SRF-binding domain was located downstream of the ETS DNA-binding domain, which was necessary for binding to SRF. Since E7 interacted with two different domains of Elk-1, the E7/Elk-1 binding may affect the protein–DNA and protein–protein interactions. These results suggest that E7 enhanced the DNA binding affinity of Elk-1 and increased the interaction between Elk-1 and SRF through the ETS DNA-binding and the SRF-binding domains, respectively. As a result, E7 may be crucial in Elk-1-SRF-SRE ternary complex formation.

Elk-1 is a member of a subfamily of ETS-domain proteins known as TCFs (ternary complex factors), which associate with the SRF to regulate c-fos proto-oncogene transcription (Gille et al., 1995; Sharrocks, 2002; Zhao et al., 2022). We observed that Elk-1 activation after interaction with E7 promotes EGR-1 and Fos gene expression at the transcriptional level (Fig. 5). This transcriptional promotion was believed to have been inhibited by the Elk-1-dominant negative EN. This suggests the importance of Elk-1 inhibition as a therapeutic strategy given that c-fos is involved in carcinogenesis. Elk-1, the most well-known TFC, is an efficient substrate for all three classes of MAPK (ERK, p38, and JNK) (Gregg and Fraizer, 2011; De Luca et al., 2012; Thiel et al., 2021). The activation of the Ras-Erk or PKC-Erk pathways by mitogen or growth factors as well as that of JNK and p38 result in Elk-1 activation (Kyrki et al., 1992; Lange et al., 1993; Wu et al., 1993).

Interestingly, Elk-1 controls various functional groups of target genes and different modes of transcription factor binding. This activates the SRF function, which acts like actin when the SRF binds to the Elk-1-SRF binding domain. SRF also controls the actin cytoskeleton and cell migration (Odrowaz and Sharrocks, 2012; Azam et al., 2022). Therefore, we can expect that the binding of E7 to the Elk-1-SRF binding domain, which we identified, functionally regulates the target gene function. Considering these aspects, as repeatedly emphasised, suppressing the activation of Elk-1 by E7 may be a good strategy for the treatment of cervical cancer.

In conclusion, E7 promotes cervical cancer in addition to deactivating pRb by binding to Elk-1, a new target of E7, and activating the function of Elk-1. We expect that blocking this accelerating process can be a good treatment strategy for suppressing cervical cancer.

CONFLICT OF INTEREST

The authors have declared that no competing interest exists.

ACKNOWLEDGMENTS

The work is supported by grants from the Basic Science Research Program through the National Research Foun-
Gonzalez, S. L., Streliau, M., He, X., Basile, J. R. and Münger, K. (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75, 7583-7591.

Gregg, J. and Fraizer, G. (2011) Transcriptional regulation of EGR1 by EGFR and the ERK signaling pathway in prostate cancer cells. Genes Cancer 2, 900-909.

Guo, C.-p., Liu, K.-w., Luo, H.-b., Chen, H.-b., Zheng, Y., Sun, S.-n., Zhang, Q. and Huang, L. (2011) Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. PLoS One 6, e17734.

Gyöngyösi, E., Szalmás, A., Ferenci, A., Könya, J., Gergely, L. and Veress, G. (2012) Effects of human papillomavirus (HPV) type 16 oncoproteins on the expression of involucrin in human keratinocytes. Virol. J. 9, 36.

Hatterschide, J., Castagnino, P., Kim, H. W., Sperry, S. M., Montone, K. T., Basu, D. and White, E. A. (2022) YAP1 activation by human papillomavirus E7 promotes basal cell identity in squamous epithelia. Elife 11, e75466.

Hwang, S. G., Lee, D., Kim, J., Seo, T. and Choe, J. (2002) Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277, 2923-2930.

Inoue, S., Ide, H., Mizushima, T., Jiang, G., Kawahara, T. and Miyamoto, H. (2018) ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor. Am. J. Cancer Res. 8, 2325-2336.

Jones, D. L. and Münger, K. (1997) Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71, 2905-2912.

Jones, D. L., Thompson, D. A. and Münger, K. (1997) Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239, 97-107.

Kawahara, T., Shareef, H. K., Aljaar, A. K., Ide, H., Li, Y., Kashiwagi, E., Netto, G. J., Zheng, Y. and Miyamoto, H. (2015) ELK1 is up-regulated in androgen in bladder cancer cells and promotes tumor progression. Oncotarget 6, 29860-29876.

Kyrtakis, J. M., App, H., Zhang, X.-F., Banerjee, P., Brautigan, D. L., Rapp, U. R. and Avruch, J. (1992) Raf-1 activates MAP kinase kinase. Nature 358, 417-421.

Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J. and Johnson, G. L. (1993) A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260, 315-319.

Kuczak, M. W. and Jagodziński, P. P. (2008) Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. Cancer Lett. 272, 53-60.

Malla, R. and Kamal, M. A. (2021) E6 and E7 oncoproteins: potential targets of cervical cancer. Curr. Med. Chem. 28, 8163-8181.

McINTYRE, M. C., Frattini, M. G., Grossman, S. R. and Laimins, L. A. (1993) Human papillomavirus type 18 E7 protein requires intact Cys-XX-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 67, 3142-3150.

Minoni, L., Romero-Medina, M. C., Venuti, A., Sirand, C., Robitaille, A., Altamura, G., Le Calvez-Kelm, F., Vianio, D., Zanier, K., Müller, M., Accardi, R. and Tommasino, M. (2020) Transforming properties of beta-3 human papillomavirus E6 and E7 proteins. mSphere 5, e00398-20.

Moody, C. A. and Laimins, L. A. (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10, 550-560.

Narisawa-Saito, M. and Kyono, T. (2007) Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 98, 1505-1511.

Nuber, U., Schwarz, S. E. and Scheffner, M. (1998) The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur. J. Biochem. 254, 643-649.

Odrowaz, Z. and Sharrackos, A. D. (2012) ELK1 uses different DNA binding modes to regulate functionally distinct classes of target motifs. PLoS Genet. 8, e1002694.

Pal, A. and Kundu, R. (2020) Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front. Microbiol. 10, 3116.
Patrick, D., Oliff, A. and Heimbrook, D. (1994) Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269, 6842-6850. 
Prathapam, T., Kühne, C. and Banks, L. (2001) The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene 20, 7677-7685. 
Putta, S., Alvarez, L., Lüdtke, S., Sehr, P., Müller, G. A., Fernandez, S. M., Trinath, S., Lewis, J., Gibson, T. J., Chemes, L. B. and Rubin, S. M. (2022) Structural basis for tunable affinity and specificity of LxCxE-dependent protein interactions with the retinoblastoma protein family. Structure 30, 1340-1353.e3. 
Rho, S. B., Byun, H.-J., Kim, B.-R. and Lee, C. H. (2022) Snail promotes cancer cell proliferation via its interaction with the BIRC3. Biomol. Ther. (Seoul) 30, 380-388. 
Rho, S. B., Byun, H. J., Kim, B.-R. and Lee, C. H. (2021a) Knockdown of LKB1 sensitizes endometrial cancer cells via AMPK activation. Biomol. Ther. (Seoul) 29, 650-657. 
Rho, S. B., Lee, K. W., Lee, S.-H., Byun, H. J., Kim, B.-R. and Lee, C. H. (2021b) Novel anti-angiogenic and anti-tumour activities of the N-terminal domain of NOEY2 via binding to VEGFR-2 in ovarian cancer. Biomol. Ther. (Seoul) 29, 506-518. 
Sharrocks, A. D. (2002) Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (tympany complex factor) subfamily. The Colworth Medal Lecture. Biochem. Soc. Trans. 30, 1-9. 
Sima, N., Wang, W., Kong, D., Deng, D., Xu, Q., Zhou, J., Xu, G., Meng, L., Lu, Y., Wang, S. and Ma, D. (2006) RNA interference against HPV16 E7 oncoprotein leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis 13, 273-281. 
Taghizadeh, E., Jahangiri, S., Rostami, D., Taheri, F., Renani, P. G., Taghizadeh, H. and Gheibi Hayat, S. M. (2019) Roles of E6 and E7 human papillomavirus proteins in molecular pathogenesis of cervical cancer. Curr. Protein Pept. Sci. 20, 926-934. 
Thiel, G., Backes, T. M., Guethlein, L. A. and Rössler, O. G. (2021) Critical protein-protein interactions determine the biological activity of Elk-1, a master regulator of stimulus-induced gene transcription. Molecules 26, 6125. 
Thierry, F. (2009) Transcriptional regulation of the papillomavirus oncoproteins by cellular and viral transcription factors in cervical carcinoma. Virology 384, 375-379. 
Vats, A., Trejo-Cerro, O., Massimi, P. and Banks, L. (2022) Regulation of HPV E7 stability by E6-associated protein (E6AP). J. Virol. 96, e0066222. 
Wang, T., Zhang, W., Huang, W., Hua, Z. and Li, S. (2021) LincRNA MALAT1 was regulated by HPV16 E7 independently of pRB in cervical cancer cells. J. Cancer 12, 6344-6355. 
Wang, X., Wu, X., Zhang, Z., Ma, C., Wu, T., Tang, S., Zeng, Z., Huang, S., Gong, C., Yuan, C., Zhang, L., Feng, Y., Huang, B., Liu, W., Zhang, B., Shen, Y., Luo, W., Wang, X., Liu, B., Lei, Y., Ye, Z., Zhao, L., Cao, D., Yang, L., Chen, X., Haydon, R. C., Luu, H. H., Peng, B., Liu, X. and He, T. C. (2018) Menesins inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci. Rep. 8, 17914. 
Wendel, S. O., Stoltz, A., Xu, X., Snow, J. A. and Wallace, N. (2022) HPV 16 E7 alters translation synthesis signaling. Research Square doi: 10.21203/rs.3.rs-1795099v1 [Preprint]. 
Winder, M. L. and Campbell, K. J. (2022) MCL-1 is a clinically targetable vulnerability in breast cancer. Cell Cycle 21, 1439-1455. 
Wu, E. W., Clemens, K., Heck, D. and Münger, K. (1993a) The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67, 2402-2407. 
Wu, J., Harrison, J., Dent, P., Lynch, K., Weber, M. and Sturgill, T. (1993b) Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MK22. Mol. Cell. Biol. 13, 4539-4548. 
Xiong, Y., Wang, Y., Ou, H. and Zhou, Y. (2022) HPV E7 oncogene expression impairs Rb function and confers CDK4/6 inhibitor resistance in cervical cancer. J. Clin. Oncol. 40, e17504. 
Yang, R., Li, X., Wu, Y., Zhang, G., Liu, X., Li, Y., Bao, Y., Yang, W. and Cui, H. (2020) EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway to glioblastoma. Oncogene 39, 2975-2986. 
Yang, X., Zhao, M., Xia, M., Liu, Y., Yan, J., Ji, H. and Wang, G. (2012) Selective requirement for Mediator MED23 in Ras-active lung cancer. Proc. Natl. Acad. Sci. U. S. A. 109, E8213-E8222. 
Yim, E.-K. and Park, J.-S. (2005) The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res. Treat. 37, 319-324. 
Yoon, Y.-C., Fang, Z., Lee, J. E., Park, J. H., Ryu, J.-K., Jung, K. H. and Hong, S.-S. (2020) Selonsertib inhibits liver fibrosis via downregulation of ASK1/MAPK pathway of hepatic stellate cells. Biomol. Ther. (Seoul) 28, 527-536. 
Zhang, J., Yu, G., Yang, Y., Wang, Y., Guo, M., Yin, Q., Yan, C., Tian, J., Fu, F. and Wang, H. (2022) A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6-E6AP-p53 axis. Pharmacol. Res. 177, 106128. 
Zhao, L., Sun, X., Chen, L., Feng, X., Yang, X., Zou, P., Wang, X. and Zhang, R. (2022) Hepatitis C virus core protein promotes the metastasis of human hepatocytes by activating the MAPK/ERK/PEA3-SRF/c-Fos/MMPS axis. Arch. Med. Res. 53, 469-482. 
Zhou, J., Peng, C., Li, B., Wang, F., Zhou, C., Hong, D., Ye, F., Cheng, X., Lü, W. and Xie, X. (2012) Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol. Oncol. 124, 296-302. 
Zhou, L., Ng, D. -S.-C., Yam, J. C., Chen, L. J., Tham, C. C., Pang, C. P. and Chu, W. K. (2022) Post-translational modifications on the retinoblastoma protein. J. Biomed. Sci. 29, 33.